Skip to main content
Equasens logo

Equasens — Investor Relations & Filings

Ticker · EQS ISIN · FR0012882389 LEI · 96950066I7XVFGZI8L92 PA Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 326 across all filing types
Latest filing 2022-03-25 Earnings Release
Country FR France
Listing PA EQS

About Equasens

https://equasens.com

Equasens is a company specializing in healthcare IT solutions for professionals and establishments. It develops and provides a range of products including professional software, electronic equipment, connected devices, and digital health solutions. The company's offerings cater to a diverse client base, including pharmacies, hospitals, nursing homes (EHPADs), home care services, and independent medical practitioners. The primary objective of its solutions is to improve the quality of patient care by facilitating the secure sharing of health data, enhancing communication between different care providers, and optimizing the coordination of care pathways across outpatient, hospital, and home care settings.

Recent filings

Filing Released Lang Actions
PHARMAGEST INTERACTIVE : Résultat Net 2021 : +25,97% à 41,15 M€  et projet de changement de nom
Earnings Release Classification · 1% confidence The document is a press release dated March 25, 2022, detailing the financial results for the year 2021 (Chiffre d'affaires, Résultat Net, Dividende proposé). It explicitly mentions the examination and approval of the 2021 accounts by the Board of Directors and notes that the certification report will be issued after finalization for the annual financial report. It provides key financial highlights, performance analysis by division, and future outlook. This structure—a summary announcement of annual financial performance released before the final audited Annual Report (10-K equivalent)—is characteristic of an Earnings Release (ER). While it contains detailed financial figures, its format as a 'COMMUNIQUE DE PRESSE' announcing the results for the year 2021 strongly points to an ER rather than the comprehensive 10-K or a standalone Audit Report (AR). It is not a transcript (CT) or a general regulatory filing (RNS) because it is specifically focused on results. FY 2021
2022-03-25 French
Pharmagest Interactive: 2021 Net Profit: +25.97% to €41.15m and new name proposal for the Group
Earnings Release Classification · 1% confidence The document is a press release dated March 25, 2022, detailing the financial results for the fiscal year 2021 (FY 2021). It explicitly mentions key financial metrics like Revenue (€193.07m), Operating Profit, and Net Profit (€41.15m), along with EPS and a dividend proposal. It also states that the Board of Directors examined and approved the accounts for fiscal 2021 and that the auditors' report will be issued after the management report review. The content is a summary of annual performance, which strongly suggests an Annual Report (10-K) or an Earnings Release (ER). Since it provides detailed financial highlights, management discussion, and outlook, it functions as the primary announcement of the full-year results, fitting the definition of an Earnings Release (ER) which typically precedes the formal 10-K filing. Furthermore, it announces a proposal for the Annual General Meeting (AGM) regarding the dividend and a name change proposal to be voted on at an Extraordinary General Meeting (EGM), but the core content is the annual financial summary. Given the structure (Press Release format summarizing full-year performance), ER is the most appropriate classification for this initial disclosure. FY 2021
2022-03-25 English
PHARMAGEST INTERACTIVE : CA 2021 : +12,41% à 193,07 M€
Earnings Release Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) and details the company's "CA 2021" (2021 Revenue/Turnover) figures, showing quarterly and annual performance comparisons. This format, focusing on key financial highlights for a completed period (2021), strongly indicates an Earnings Release (ER). It is not the full Annual Report (10-K) as it states the annual figures are "non audité" (unaudited) and it is a summary press release. It also provides a future date for the 'Résultats Annuels 2021' (March 25, 2022), confirming this document is the preliminary announcement of results, which aligns perfectly with the Earnings Release (ER) definition. FY 2021
2022-02-04 French
Pharmagest Interactive: 2021 revenue: €193.07m, up 12.41%
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the "2021 revenue: €193.07m, up 12.41%" along with detailed segment performance and a 2022 outlook. This format, focusing on key financial highlights for a completed period (2021) immediately following the period end, strongly indicates an Earnings Release (ER). It is not the full Annual Report (10-K) as it states the FY 2021 Annual Results will be released on March 25, 2022, and the revenue figures are marked as '* unaudited*'. It is also not a Call Transcript (CT) or Investor Presentation (IP) as it is a formal press release summary. FY 2021
2022-02-04 English
PHARMAGEST INTERACTIVE : Bilan semestriel S2 2021 du contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "BILAN SEMESTRIEL S2-2021 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" (Half-Year Balance Sheet S2-2021 of the Liquidity Contract with Gilbert Dupont Stock Brokerage). It details the status of a liquidity contract (stock buy/sell activity) as of December 31, 2021, covering the second half of 2021. This type of filing reports on the company's own share transactions conducted under a liquidity agreement, which falls under the category of transactions in own shares (share repurchase/issuance). The specific code for this activity is POS (Transaction in Own Shares). It is not a general earnings release (ER) or a comprehensive interim report (IR), but a specific regulatory disclosure related to market making/liquidity management.
2022-01-27 French
PHARMAGEST INTERACTIVE : Nouvelle direction générale
Board/Management Information Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary content announces significant changes in the company's senior management structure, specifically naming the proposed new CEO (Denis SUPPLISSON) and other executive appointments. This directly aligns with the definition of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management. The document is not a full annual report (10-K), an earnings release (ER) focusing on financial figures, or a transcript (CT).
2021-12-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.